Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Palatin Technologies (PTN)

Palatin Technologies (PTN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders FinancialNewsMedia - Thu Oct 19, 2023

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

PTN : 1.7200 (-6.52%)
RYTM : 39.01 (+2.63%)
VKTX : 63.85 (+0.68%)
GPCR : 36.02 (-0.94%)
NVO : 125.26 (+2.08%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...

PTN : 1.7200 (-6.52%)
RYTM : 39.01 (+2.63%)
VKTX : 63.85 (+0.68%)
GPCR : 36.02 (-0.94%)
NVO : 125.26 (+2.08%)
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 1.7200 (-6.52%)
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients PR Newswire - Wed Oct 18, 2023

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 1.7200 (-6.52%)
Palatin Receives Notice of Non-Compliance from NYSE American PR Newswire - Fri Oct 13, 2023

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 1.7200 (-6.52%)
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update PR Newswire - Thu Sep 28, 2023

Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023...

PTN : 1.7200 (-6.52%)
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023 PR Newswire - Fri Sep 22, 2023

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday,...

PTN : 1.7200 (-6.52%)
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire - Thu Sep 7, 2023

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 1.7200 (-6.52%)
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease PR Newswire - Thu Sep 7, 2023

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 1.7200 (-6.52%)
PLN Signs Cooperation with TANESCO to Develop Electricity Ecosystem in Tanzania ACN Newswire - Mon Sep 4, 2023

PLN Signs Cooperation with TANESCO to Develop Electricity Ecosystem in Tanzania

PTN : 1.7200 (-6.52%)

Barchart Exclusives

1 Cheap Dividend King With 14% Upside Potential Barchart - Mon Apr 22, 6:30PM CDT
As the energy sector rides out the latest wave of volatility, one undervalued company with a fully integrated business model stands out from the crowd for income-seeking investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot